Avantor vs Personalis: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Avantor Inc (AVTR)

Q3 202613 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

August 202613 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

Latest13 Jul – 18 Sep 2026

▲3

Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion

Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.

Personalis Inc (PSNL)

Q3 202620 Jul – 6 Oct 2026

▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.
The takeover itself is the single biggest force setting PSNL's price.
Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.
Legal challenges are a real counterweight that could change deal terms or timing.
Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.
The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.
Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.
This explains why PSNL trades near the deal price instead of rallying on takeover hopes.

August 202620 Jul – 6 Oct 2026

▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.
The takeover itself is the single biggest force setting PSNL's price.
Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.
Legal challenges are a real counterweight that could change deal terms or timing.
Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.
The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.
Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.
This explains why PSNL trades near the deal price instead of rallying on takeover hopes.

Latest20 Jul – 6 Oct 2026

▲2▼2

Personalis stuck near $16.25 Tempus buyout as higher bid hopes fade

Tempus to buy Personalis at $16.25 a share Tempus AI agreed to buy Personalis for $16.25 a share, about $1.5 billion, a premium to where the stock traded before the news. That buyout price now acts like a ceiling and a floor for the shares, anchoring PSNL near the deal value.
The takeover itself is the single biggest force setting PSNL's price.
Law firms question whether the sale price is fair Several investor-rights law firms opened investigations into whether Personalis's board ran a fair sale process, given Tempus's existing stake and partnership. This adds uncertainty and keeps alive the small chance of a bump in price or extra disclosures, but no higher offer has appeared.
Legal challenges are a real counterweight that could change deal terms or timing.
Tempus's health strengthens the buyer's stock Tempus returned to profit, raised its 2026 revenue outlook, and its mRNA melanoma trial succeeded, sending its shares sharply higher. Because part of the Personalis price is paid in Tempus stock, a stronger Tempus makes the deal look more secure and valuable to PSNL holders.
The buyer's improving finances and trial win directly support the value of the stock-and-cash consideration.
Analysts see no competing bid, downgrade PSNL Craig-Hallum and BTIG downgraded Personalis, saying a higher bid is unlikely because Tempus is the key seller of Personalis's MRD test and Merck, a big shareholder, backs the deal. The stock fell on that view, as investors accept the $16.25 price is probably final.
This explains why PSNL trades near the deal price instead of rallying on takeover hopes.